Stock screener

CBIO

Conviction 42HealthcareScan · Thu, Sep 24, 2026

Crescent Biopharma, Inc. (CBIO) closed at $14.24 (+0.35%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 32, RS Rating 48, -47.2% from its 52-week high, +28.5% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

CBIO$14.24+0.35%
ResistanceSupportVol 14
63 bars
Vol MA14 824.31K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
CRESCENT BIOPHARMA, INC.PHARMACEUTICAL PREPARATIONSwww.crescentbiopharma.com ↗
Price14.24
Change+0.35%
Gap-1.30%
Rel volume6.83×
Avg volume685.29K
Avg $ vol11.53M
SMA 2017.98
SMA 5016.99
SMA 20015.72
Price vs 50-16.17%
Price vs 200-9.42%
MA stackmixed
50/200 cross—
Supertrenddown · 18.48
RSI (14)32
MACD hist-0.61
MACD crossbear · 6d
Stoch %K / %D10 / 9
ADX (14)23
+DI / −DI13 / 30
RSI divergence—
MACD divergence—
ATR %10.28%
ADR %8.55%
52w high26.98
52w low8.94
From 52w high-47.22%
Above 52w low+59.28%
New 52w highNo
SqueezeOff
Bollinger width42.09%
%B0.01
Donchian pos9.10%
Donchian high22.33
Donchian low13.43
AVWAP (52w high)17.65
vs AVWAP high-19.31%
AVWAP (52w low)16.98
vs AVWAP low-16.12%
OBV trendUp
Chaikin MF (20)-0.01
Today vs 20d6.83×
Avg vol (14d)824.31K
Avg vol (20d)685.29K
Avg $ vol (20d)11.53M
Market cap528.93M
RS Rating48 / 99
RS 3m (vs SPY)-20.68%
RS 6m (vs SPY)+4.07%
RS line new highNo
Trend template3/8
Technical rank28.2
1 week-15.09%
1 month-16.24%
3 months-16.19%
6 months+20.88%
1 year+9.96%
YTD+28.52%
P/E-3.44
P/B3.24
P/S48.78
P/FCF-7.30
EPS-0.5900
Div yield—
ROE-94.30%
ROA-84.23%
Debt/Eq—
Current9.66
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-306.40%
Price target27.67
Target upside94.31%
Analyst ratingBuy
Institutional81.21%
Ent. value357.34M
Revenue0
Net income-24.84M
Gross profit—
Free cash flow-72.45M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out—
Employees44
ListedMon, Jun 16, 2025
Free float18.11M
Float %65.7%
Short interest3.17M
Days to cover19.9d
Short volume75.8%
Squeeze score95 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.74 vs −$0.78
Last surprise+5.1% beat
Setup gradeD
Conviction42 / 100
Pattern quality—
Tech rank28.2 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance21.37
Support16.07
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CBIO

All disclosures →
No recent disclosed trades by Congress in CBIO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CBIO

InsiderSideShares
Violin Jonathan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Moran Susan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Fairmount Healthcare Fund II L.P.
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Fairmount Funds Management LLC
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Lubner David Charles
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Harwin Peter Evan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Kiselak Tomas
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Balcom Alexandra
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K

SEC filings

EDGAR filings in CBIO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.